DuLac Farmaceutici, an Italian pharmaceutical company, is accelerating its expansion into the U.S. market with the announcement that its products are now available through OneLavi.com. The company is also preparing to participate in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These developments represent strategic steps in DuLac's plan to significantly increase its footprint in the United States.
After establishing consumer demand through Amazon U.S., DuLac is adding a new e-commerce channel with OneLavi while preparing to introduce its brand to major U.S. retailers at ECRM. The company views the U.S. as a significant long-term growth market and is building a diversified presence that combines Amazon demand, expanded e-commerce availability, and direct engagement with retailers and distribution partners.
"ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market," said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. "Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
DuLac's U.S. growth is supported by strong consumer response on Amazon, with its Arnica Gel 98% earning more than 13,000 customer reviews and an average 4.5-star rating, while the Dinaven line has received more than 4,000 reviews and maintains a 4.6-star rating. The addition of OneLavi provides another platform to introduce the Made in Italy portfolio to American consumers.
Participation at ECRM adds a business-to-business dimension to DuLac's strategy. During the session, DuLac will meet with buyers from major health, specialty, food, drug, and mass retail channels, highlighting its Italian-developed products, pharmaceutical heritage, and advanced manufacturing capabilities. Among the products featured will be the high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines.
DuLac's objective extends beyond additional points of distribution; the company aims to establish relationships that support a larger and more diversified U.S. retail presence. With more than 30 years of pharmaceutical expertise, DuLac brings proprietary technologies such as Arnica Montana Arricchita™, indoor vertical farming, micronized Diosmin MPFF technology, and solvent-free Supercritical CO₂ Extraction, all under GMP and ISO quality frameworks.
The combination of Italian pharmaceutical heritage, research, advanced production, established Amazon demand, and growing U.S. distribution provides a solid foundation for DuLac's next stage of growth. With Amazon already established, OneLavi now live, and scheduled meetings at ECRM, DuLac is transitioning from initial market development to a broader national expansion strategy, aiming to build a diversified presence across e-commerce, retail, wholesale, and other channels while introducing more American consumers to its brand.
